Drugs / MAX-40279-01
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05369286 | Apr 2022 → May 2023 | cancer | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04183764 | Nov 2019 → Nov 2022 | cancer | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04187495 | Apr 2019 → Dec 2022 | acute myeloid leukemia | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05425602 | Jul 2022 → Dec 2023 | — | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05061147 | Sep 2021 → Apr 2022 | acute myeloid leukemia, myelodysplastic syndrome | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05130021 | Jan → May 2022 | colorectal cancer | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAX40279-01 | “Drug: Stage1: Dose1:MAX40279-01 (35mg BID)+KN046 ( 5mg/kg Q3Week)” NCT05425602 ↗6“Drug: Max-40279-01 Max-40279-01 will be administered” NCT05061147 ↗ |
| Known as | MAX-40279 | “Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)” NCT04187495 ↗ |
| Action | Inhibit | “Multi-target Tyrosine Kinase Inhibitor” NCT05425602 ↗ |
| Route | Oral | “will be first administered orally” NCT04187495 ↗ |